I learned that Emmes had a very good reputation with public sector clients while working at a US Government contracting firm. I later had an opportunity to work with the Emmes team on several projects and confirm earlier observations about its professionalism and scientific/technical capabilities.

A data first clinical research organization

My wife and I wanted to remain in the Washington, DC area following my post-doctoral work at NIH. At that time the Prescription Drug User Fee Act was being implemented and created an opportunity to continue my interests in virology at FDA and remain in Maryland.

While I do enjoy the camaraderie/multidisciplinary team approach at Emmes, I’m particularly engaged in the varied and interesting clinical problems we are able to tackle.

My scientific background is in viral immunology. I worked at FDA as a product reviewer and acting deputy director before joining a large US Government contractor where our life science group provided biomedical product development and regulatory affairs support.

Ph.D. Pennsylvania State University College of Medicine

Production Assistance for Cell Therapy | Cure Sickle Cell Initiative | NIDA Coordinating Center

El Fiky A, Ibenana L, Anderson R, Hare J, Khan A, Gee AP, Rooney C, McKenna DH, Gold J, Kelley L, Lundberg M, Welniak L, Lindblad R. The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) Program: Eighteen Years of Cell Therapy. Manuscript submitted for review.
Nicole Fisher, Laarni Ibenana, Ashraf ElFiky, Robert Anderson, Regulation of Cellular Therapy in the United States, in Cell Therapy: cGMP Facilities and Manufacturing, edited by Adrian Gee, Second Edition, 2021, Springer Publishing.